Short Interest in Genenta Science S.p.A. (NASDAQ:GNTA) Declines By 40.0%

Genenta Science S.p.A. (NASDAQ:GNTA) experienced a notable decline in short interest during February. As of February 28th, total short interest amounted to 1,500 shares, reflecting a decrease of 40.0% from 2,500 shares on February 13th. At this time, approximately 0.0% of the company's stock is sold short. Based on an average daily trading volume of 10,400 shares, the short-interest ratio stands at just 0.1 days.

Institutional Investors Involvement with Genenta Science

In recent developments, Citadel Advisors LLC, a hedge fund, has acquired a new stake in Genenta Science. According to their latest disclosure with the Securities and Exchange Commission (SEC), the hedge fund purchased 11,167 shares of Genenta Science stock during the fourth quarter, representing an investment of approximately $46,000. Following this acquisition, Citadel Advisors LLC now holds 0.06% of the company's total shares. Overall, institutional investors and hedge funds control about 15.13% of Genenta Science's stock.

Performance of Genenta Science Stock

On the last trading session, GNTA stock saw a decrease of $0.11, reaching a value of $3.84. The trading volume during this session was 1,273 shares, which is lower than the average volume of 8,263 shares. Genenta Science's stock has shown a 50-day moving average of $4.07 and a 200-day moving average of $4.54. Over the past year, the stock recorded a low of $2.20 and a high of $7.28.

Overview of Genenta Science

Genenta Science S.p.A. is a biotechnology company in the clinical stage, focusing on the development of hematopoietic stem cell gene therapies for treating solid tumors in Italy. The company's lead candidate, Temferon, is currently in Phase 1/2a clinical trials, targeting glioblastoma multiforme in patients with an unmethylated MGMT gene promoter.

Additional Insights

• Stocks to Consider Instead of Genenta Science
• Understanding Special Dividends
• Casey’s Positive Trend Continues—Expect New Highs
• Steps to Trade Penny Stocks Effectively
• Impact of Taiwan Semiconductor’s Major U.S. Developments
• Insights on Consumer Discretionary Stocks
• Potential of Costco Stock Reaching $1,000 Again Soon

This information is generated using advanced technology to provide the quickest and most accurate updates. The editorial team reviews all reports before publication. For questions or feedback, please contact us via email.

Investment Considerations for Genenta Science

Before making any investment decisions regarding Genenta Science, it is advisable to consider additional factors. Analysts often track the top performing stocks and their recommendations. Currently, Genenta Science retains a Buy rating, but there are five other stocks highlighted by leading analysts that they believe are more promising investments.

Explore More on Top Stocks to Consider

Genenta, Science, Stock